Table 1 Antimicrobial susceptibility profiles.R, resistant; I, intermediate; S, susceptible
Antimicrobial classes | Antimicrobial drugs | MIC (mg/L) and Susceptibility | |||||||
|---|---|---|---|---|---|---|---|---|---|
BJ1 | BJ2 | BJ3 | BJ4 | BJ5 | BJ6 | BJ7 | BJ8 | ||
Aminoglycosides | Gentamicin (CN) | >8, R | >8, R | >8, R | ≤1, S | >8, R | >8, R | >8, R | >8, R |
Amikacin (AK) | ≤16, S | >32, R | >32, R | ≤2, S | >32, R | ≤16, S | ≤16, S | >32, R | |
Antipseudomonal carbapenems | Imipenem (IPM) | >8, R | >8, R | >8, R | ≤1, S | >8, R | >8, R | >8, R | ≤1, S |
Antipseudomonal fluoroquinolones | Ciprofloxacin (CIP) | >2, R | >2, R | >2, R | ≤0.25, S | >2, R | >2, R | >2, R | >2, R |
Lavo-ofloxacin (LEV) | >4, R | >4, R | >4, R | ≤0.25, S | >4, R | >4, R | >4, R | =4, I | |
Antipseudomonal penicillins and β-lactamase inhibitors | Piperacillin-tazobactam (TZP) | >64/4, R | >64/4, R | >64/4, R | ≤4, I | >64/4, R | >64/4, R | >64/4, R | ≤16/4, S |
Extended-spectrum cephalosporins | Ceftriaxone (CTR) | >32, R | >32, R | >32, R | 8, R | >32, R | >32, R | >32, R | >32, R |
Ceftazidime (CAZ) | >16, R | >16, R | >16, R | 4, I | >16, R | >16, R | >16, R | >16, R | |
Cefepime (FEP) | >16, R | >16, R | >16, R | 2, S | >16, R | >16, R | >16, R | >16, R | |
Polymyxins | Polymyxin B (PB) | ≤2, S | ≤2, S | ≤2, S | ≤2, S | ≤2, S | ≤2, S | ≤2, S | ≤2, S |
Tetracyclines | Tetracycline (TE) | =8, I | >8, R | >8, R | ≤4, S | >8, R | >8, R | >8, R | >8, R |